# US 9,005,615 B2 · Methods for treatment of inflammatory diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,005,615 B2
- Document ID: US9005615B2
- Status: Granted
- Kind: B2
- Application number: 13/696,316
- Filed: 2011-05-05
- Published: 2013-03-21
- Granted: 2015-04-14
- Earliest claimed: 2010-05-06
- Assignees: The Feinstein Institute for Medical Research
- Applicants: Kevin Tracey; Sangeeta Chavan
- Inventors: Kevin Tracey; Sangeeta Chavan
- Web page: https://patentgrep.com/patent/US9005615B2

## CPC

- A61K 39/39533: {against materials from animals}
- C07K 16/22: against growth factors {; against growth regulators}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides methods of treating inflammatory diseases in a subject comprising administering to the subject a therapeutically effective amount of an agent that inhibits pigment epithelium-derived factor (PEDF) and methods of screening for agents that inhibit PEDF.

## Claims

### Claim 1

A method of treating a disease or disorder in a subject, the method comprising administering to the subject a therapeutically effective amount of an antibody that binds to and inhibits pigment epithelium-derived factor (PEDF), wherein the disease or disorder is selected from the group consisting of endotoxemia, sepsis, septicemia, and endotoxic shock.

### Claim 2 (depends on 1)

The method of claim 1, wherein the disease or disorder is endotoxemia.

### Claim 3 (depends on 1)

The method of claim 1, wherein the disease or disorder is sepsis.

### Claim 4 (depends on 1)

The method of claim 1, wherein the disease or disorder is septicemia.

### Claim 5 (depends on 1)

The method of claim 1, wherein the disease or disorder is endotoxic shock.

### Claim 6 (depends on 1)

The method of claim 1, wherein the antibody is a monoclonal antibody.

### Claim 7 (depends on 1)

The method of claim 1, wherein the antibody is a humanized or human antibody.

### Claim 8 (depends on 1)

The method of claim 1, wherein the subject is a mammal.

### Claim 9 (depends on 8)

The method of claim 8, wherein the subject is a human.